| S7138 |
BMS-833923
|
BMS-833923 (XL139) is an orally bioavailable Smoothened antagonist. Phase 2.
|
-
Nat Commun, 2025, 16(1):4983
-
Sci Rep, 2022, 12(1):7
-
Mol Cancer Res, 2021, molcanres.MCR-21-0257-A.2021
|
|
| S2157 |
Taladegib (LY2940680)
|
Taladegib (LY2940680) binds to the Smoothened (Smo) receptor and potently inhibits Hedgehog (Hh) signalling in Phase 1/2.
|
-
Sci Rep, 2022, 12(1):7
-
Carcinogenesis, 2020, 41(7):993-1004
-
Front Pharmacol, 2019, 10:89
|
|
| S7160 |
Glasdegib
|
Glasdegib is a potent, and orally bioavailable Smoothened (Smo) inhibitor with an IC50 of 5 nM. Phase 2.
|
-
J Extracell Vesicles, 2025, 14(9):e70163
-
iScience, 2024, 27(10):110862
-
Leukemia, 2023, 37(8):1649-1659
|
|
| S9743 |
Ciliobrevin D
|
Ciliobrevin D (compound 5) is a cell-permeable, reversible and specific antagonist of AAA+ (ATPases associated with diverse cellular activities) ATPase motor cytoplasmic dynein. This compound perturbs primary cilia formation and blocks Hedgehog (Hh) signalling.
|
-
Cell Prolif, 2025, e13819.
-
ACS Chem Biol, 2024, 19(8):1733-1742
-
Mol Cell, 2022, S1097-2765(22)00327-6
|
|
| S2777 |
PF-5274857
|
PF-5274857 is a potent and selective Smoothened (Smo) antagonist, inhibits Hedgehog (Hh) signalling with IC50 and Ki of 5.8 nM and 4.6 nM, respectively, and this compound can penetrate the blood–brain barrier.
|
-
Sci Rep, 2022, 12(1):7
-
Biol Reprod, 2021, ioab111
-
Carcinogenesis, 2020, 41(7):993-1004
|
|
| S4747 |
Jervine
|
Jervine (11-Ketocyclopamine) is a Hedgehog signaling (IC50=500-700 nM) inhibitor that inhibits the sonic hedgehog (shh) pathway by interacting with smoothened.
|
-
FASEB J, 2025, 39(20):e71187
-
Sci Rep, 2022, 12(1):7
-
Neurochem Int, 2021, 146:105042
|
|
| S8200 |
MK-4101
|
MK-4101, a potent inhibitor of the Hedgehog pathway, shows anti-tumour activity through the inhibition of proliferation and induction of extensive apoptosis in tumour cells.
|
-
Sci Rep, 2022, 12(1):7
|
|
| S6565 |
JK184
|
JK184 inhibits Gli in the Hedgehog (Hh) pathway with an IC50 of 30 nM in mammalian cells.
|
-
Cell Res, 2020, 10.1038/s41422-020-00426-0
|
|
| E0787 |
ALLO-2
|
ALLO-2 is a potent antagonist of both wild-type mouse Smo and drug-resistant D473H mutant human Smo that inhibits Smo agonist inhibited Gli-Luc activity in TM3-Gli-Luc cells with IC50 of 6 nM.
|
|
|
| S1182New |
GANT58(NSC75503)
|
GANT 58 (NSC 75503) is a potent antagonist of GLI-mediated transcription with an IC50 of ≈5 μM. It can be used for research into Ewing Sarcoma and several forms of solid cancer.
|
|
|
| E0480 |
MRT-81
|
MRT-81 is a potent antagonist of human and rodent smoothened (Smo) receptors, with an IC50 value of 41 nM in the Shh-light2 cells, exerting potent hedgehog (Hh) signalling pathway inhibiting activity.
|
|
|
| E0782 |
MRT 10
|
MRT-10 inhibits ShhN signalling in Shh-light2 cells in a dose-dependent manner with IC50 of 0.64 μM, showing the capacity to abrogate the constitutive activity of Smo.
|
|
|